Get the Stockscreener App
114.45
0.87%
-1.00
After Hours:
114.45
Sarepta Therapeutics Inc Stock (SRPT) Latest News
Mucopolysaccharidosis Type III Pipeline 2024: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Takeda Pharma, BioMarin Pharma, Ultragenyx Pharma, Sarepta - Barchart
Sarepta could be down on patient death in FDA database, says RBC Capital - Yahoo Finance
Stock Market Movers Today • Top Gainers & Losers - Benzinga
Arrowhead Pharma Stock Soars Pre-Market On $825M Sarepta Licensing Deal: Retail Activity Hits Year-High - MSN
Cancer Gene Therapy Market Outlook 2025-2032: Witness Booming - openPR
Sarepta’s DMD Gene Therapy Elevidys Shows Sustained Benefit in Updated Phase 3 Data - CGTLive™
Mizuho maintains Sarepta stock with $195 target on trial data - MSN
Neuromuscular Disease Therapeutics Market to grow by USD 13.73 Billion (2025-2029), novel approvals for neuromuscular treatments boost growth, AI-powered market evolutionTechnavio - The Malaysian Reserve
Sarepta Therapeutics' SWOT analysis: gene therapy leader's stock faces pivotal year - Investing.com India
Pulmonary Fibrosis Clinical Trial Pipeline Appears Robust With 110+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - GlobeNewswire Inc.
BMO maintains Outperform on Sarepta stock, $200 target - MSN
Roche reports positive topline outcomes from DMD treatment trial - Yahoo Finance
Sarepta buoyed by additional phase 3 data for Duchenne treatment Elevidys - MSN
Needham & Company LLC Reaffirms Buy Rating for Sarepta Therapeutics (NASDAQ:SRPT) - MarketBeat
Sarepta Therapeutics' Duchenne Gene Therapy Shows Sustained Benefits And Disease Stabilization At Two Years - Benzinga
Sarepta Therapeutics Announces Results from Part 2 of the EMBARK Study Demonstrating Sustained Benefits and Disease Stabilization in Ambulatory Individuals with Duchenne Muscular Dystrophy Following Treatment with ELEVIDYS - BioSpace
Sarepta's ELEVIDYS Shows Remarkable Success in Duchenne Muscular Dystrophy Trial - StockTitan
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
William Blair Issues Optimistic Estimate for SRPT Earnings - MarketBeat
Mucopolysaccharidosis (MPS) Treatment Market Growth in Future - openPR
Sarepta Therapeutics, Inc. (SRPT): A Bull Case Theory - MSN
Duchenne Muscular Dystrophy Clinical and Non-Clinical - openPR
Leerink Partnrs Issues Optimistic Estimate for SRPT Earnings - MarketBeat
These 4 Measures Indicate That Sarepta Therapeutics (NASDAQ:SRPT) Is Using Debt Reasonably Well - Simply Wall St
Smith Salley Wealth Management Buys Shares of 7,308 Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Biogen, Sarepta Quick Drug Approvals Show FDA Gaps, Report Says - MSN
Assenagon Asset Management S.A. Sells 217,594 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Undercovered Dozen: Lincoln National, Whitecap Resources, NMI Holdings, Healwell AI + - Seeking Alpha
What is HC Wainwright's Forecast for SRPT FY2024 Earnings? - MarketBeat
Sarepta Therapeutics: Guidance Suggests A Year Of Upside Likely (NASDAQ:SRPT) - Seeking Alpha
Sarepta Therapeutics (NASDAQ:SRPT) Given "Sell" Rating at HC Wainwright - MarketBeat
HC Wainwright Issues Optimistic Forecast for SRPT Earnings - MarketBeat
Sarepta preliminary Q4 revenue beats, but full year just misses - MSN
What 14 Analyst Ratings Have To Say About Sarepta Therapeutics - Benzinga
J&J files a potential blockbuster; Lykos shakes up its board - BioPharma Dive
HC Wainwright Reaffirms Sell Rating for Sarepta Therapeutics (NASDAQ:SRPT) - MarketBeat
Harbor Capital Advisors Inc. Acquires 427 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - Defense World
Sarepta, Biogen drugs with accelerated approval under fire in FDA report - Seeking Alpha
Biogen, Sarepta Quick Drug Approvals Show FDA Gaps, Report Says | Company Business News - Mint
Sarepta Bullish After Another Big Beat For Elevidys - News & Insights
Sarepta Therapeutics' (SRPT) "Buy" Rating Reiterated at Needham & Company LLC - MarketBeat
U.S, Europe And GCC Antisense Oligonucleotide (ASO) - openPR
Sarepta Previews Q4 Findings, Touts Elevidys Earnings Beat - BioSpace
Neuromuscular Disease Therapeutics Market to Grow by USD 13.73 Billion from 2025-2029, Driven by Novel Approvals and AI-Driven Market TransformationTechnavio - The Malaysian Reserve
Sarepta exceeds revenue forecasts, maintains 2025 guidance - Investing.com India
Sarepta Therapeutics Tops 2024 Net Product Revenue Guidance - MarketWatch
Sarepta Therapeutics (SRPT) Reports Preliminary Fourth Quarter and Full-Year 2024 Net Product Revenue - StreetInsider.com
Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2024 Net Product Revenue - Business Wire
Dyno Therapeutics Announces Exercise of Option by Roche for Next-Generation AAV Vector for Neurological Gene Therapy - Business Wire
5.49%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):